DOES TESTING FOR SAA IS MORE BENEFICIAL THAN CRP FOR THE FOLLOW-UP OF FMF PATIENTS WITH M694V HETEROZYGOUS OR M694V HOMOZYGOUS MUTATIONS?
Bağlantı
http://hdl.handle.net/20.500.12627/4690https://doi.org/10.1136/annrheumdis-2020-eular.5625
Koleksiyonlar
- Bildiri [64839]